References
- Veitonmäki N, Hansson M, Zhan F, Sundberg A, Löfstedt T, Ljungars A, et al. A human icam-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell 2013; 23:502 - 15; http://dx.doi.org/10.1016/j.ccr.2013.02.026; PMID: 23597564
- Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen TH, Srinivasan M, et al. Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells. Cancer Immunol Res 2013; http://dx.doi.org/10.1158/2326-6066.CIR-13-0013
- Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18:160 - 70; http://dx.doi.org/10.1016/j.ccr.2010.06.014; PMID: 20708157
- Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443 - 6; http://dx.doi.org/10.1038/74704; PMID: 10742152
- Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:1789 - 96; http://dx.doi.org/10.1200/JCO.2007.14.8957; PMID: 18347005
- Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011; 117:4519 - 29; http://dx.doi.org/10.1182/blood-2010-07-296913; PMID: 21378274
- Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103:2738 - 43; http://dx.doi.org/10.1182/blood-2003-06-2031; PMID: 14551143
- Fransson J, Tornberg UC, Borrebaeck CA, Carlsson R, Frendéus B. Rapid induction of apoptosis in B-cell lymphoma by functionally isolated human antibodies. Int J Cancer 2006; 119:349 - 58; http://dx.doi.org/10.1002/ijc.21829; PMID: 16477633
- Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009; 114:3625 - 8; http://dx.doi.org/10.1182/blood-2009-05-220285; PMID: 19710503
- Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y, et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 2013; 27:702 - 10; http://dx.doi.org/10.1038/leu.2012.272; PMID: 22996336